pharmaphorum3d
MSD starts pivotal trial of ROR1 drug in first-line lymphoma
ROR1 is a cellular protein normally found in ... has been discontinued, along with CAR-T therapies from Lyell and Oncternal, on toxicity issues. DLBCL accounts for up to 30% of all NHL cases ...
pharmaphorum3d
ASH: MSD’s ROR1 drug hits the target in first-line lymphoma
The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.
Nasdaq7d
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
IM-1021 is an optimized, ROR1-targeted ADC that incorporates Immunome’s proprietary TOP1 inhibitor, HC74. The Phase 1 trial is an open-label, multicenter dose escalation and expansion study ...
Morningstar11d
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase ...
manilatimes1mon
BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA
BR111 is an antibody-drug conjugate (ADC) targeting dual epitopes of ROR1, intended for the treatment of ROR1-positive hematological malignancies and solid tumors. ROR1 is a transmembrane receptor ...
manilatimes11d
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase II ...